Programmed cell death 1 inhibitor sintilimab plus concurrent chemoradiotherapy for locally advanced pancreatic adenocarcinoma

Table 1 Patient characteristics

Feature	Observation group	Control group
Age in yr
Median	57	55
Range	18-70	49-80
Sex
Male	20	16
Female	14	14
Performance status
0	29	28
1	5	2
Stage
Stage A	21	17
Stage B	13	13

Table 2 Summary of tumor response and survival outcomes according to Response Evaluation Criteria in Solid Tumors 1.0 criteria

Outcomes	Observation group, n = 34	Control group, n = 30	P value
Best tumor response
Complete response	0 (0)	0 (0)
Partial response	11 (32.4)	6 (20.0)
Stable disease	19 (55.9)	18 (60.0)
Progressive disease	4 (11.8)	6 (20)
Objective response rate	11 (32.4)	6 (20)
Disease control rate	30 (88.2)	24 (80)
Median OS in month	22.1 ± 2.6 (16.3-27.6)	17.8 ± 2.3 (12.9-22.8)	< 0.05
Median PFS in month	12.2 ± 3.1 (5.5-18.3)	10.1 ± 2.2 (5.8-14.2)	< 0.05

¹Data are n (%) or mean ± standard deviation (95% confidence interval).

OS: Overall survival; PFS: Progression-free survival.

Table 3 Toxicity

Symptom	Control group, No. of patients				Observation group, No. of patients
	Grade 1	Grade 2	Grade 3	Grade 4	Grade 1	Grade 2	Grade 3	Grade 4
Leukopenia	11	7	3	1	12	8	4	1
Fatigue	15	6	2	0	16	9	2	0
Anemia	14	5	1	0	15	6	1	0
Nausea	18	8	0	0	20	10	1	0
Anorexia	8	5	0	0	11	7	0	0